# Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct06241781/  
OnCo record `nct06241781` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine in cervical cancer, run by Grit Biotechnology, now recruiting.

## Summary

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06241781 by Grit Biotechnology, with 83 participants planned, started 2024-04-02 and due to reach its primary completion in 2027-01-31. Interventions recorded: GT101 injection and Gemcitabine injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06241781
- Phase: 2
- Setting: A Phase 2, Multicenter Randomized Controlled Open-label Study of Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
- Sponsor: Grit Biotechnology
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT06241781: https://clinicaltrials.gov/study/NCT06241781

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06241781.json